General Statement of Disclosure:

CONSULTING FEES/HONORARIA: BMS(MODEST), Boehringer-Ingelheim(SIGNIFICANT), Pfizer (MODEST), Alnylam(MODEST), Amgen(SIGNIFICANT), Amarin(MODEST), Merck(SIGNIFICANT), Aegerion(SIGNIFICANT), Ascendia(MODEST), Eli Lilly and Company(MODEST), Janssen Pharmaceuticals, Inc(MODEST), RhoShan(MODEST), Sanofi-Aventis(SIGNIFICANT), Lexicon(MODEST) RESEARCH/RESEARCH GRANTS: Boehringer-Ingelheim(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT), BMS(SIGNIFICANT), Merck(SIGNIFICANT), Amgen(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), Pfizer(SIGNIFICANT), Better Therapeutics(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT)

View Full Disclosure